SHANGHAI, Feb. 8, 2026 — WuXi Biologics (2269.HK) has announced its receipt of a Platinum Medal from the EcoVadis Sustainability Rating. This achievement marks the third consecutive year the company has earned this top-tier recognition.

EcoVadis is a globally trusted and extensive platform for sustainability assessments, analyzing corporate ESG performance against 21 criteria within four core categories: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

Ranking within the top 1% of over 150,000 companies assessed worldwide, WuXi Biologics’ Platinum Medal underscores its strong policies, meticulous execution frameworks, and demonstrated results across all ESG aspects, as verified by external stakeholders and independent experts.

How WuXi Biologics Earns the Highest EcoVadis Rating?

The company consistently enhances its sustainability efforts in the areas evaluated by EcoVadis. Key recent initiatives are:

SBTi–Approved Targets: The Science Based Targets initiative (SBTi) has validated WuXi Biologics’ near-term and net-zero greenhouse gas (GHG) emissions reduction goals, positioning the company as an industry pioneer with approval for both target types.

Green CRDMO White Paper: Published to drive sustainability in the biologics sector, this White Paper outlines WuXi Biologics’ green innovation technologies throughout research, development, and manufacturing, highlighting substantial carbon reductions from eco-friendly operations. It also aggregates 242 energy-saving examples across five major scenarios, 12 typical energy systems, and 25 technology categories.

ISO 20400 Certification: The company has obtained ISO 20400 Sustainable Procurement certification, an international benchmark that merges sustainability principles with procurement processes, fostering transparency and accountability throughout the supply chain.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, stated, “We are delighted to again receive the EcoVadis Platinum Medal, acknowledging our progress in building sustainability capabilities. As a global Green CRDMO leader, we are dedicated to maintaining exceptional ESG performance, helping partners worldwide achieve their ESG objectives, and collaborating with all stakeholders to encourage responsible practices across the full value chain.”

A Long-Term Commitment to Sustainable Value Creation

Securing the EcoVadis Platinum Medal for a third straight year further solidifies global clients’ trust in WuXi Biologics’ dependability, accountability, and visionary approach. The company maintains a steadfast commitment to high sustainability, quality, and compliance standards to foster enduring partnerships within the dynamic global ESG environment.

As a member of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics actively promotes sustainability and has garnered extensive accolades. These include an MSCI AAA Rating; inclusion in the Dow Jones Sustainability Indices (DJSI); placement on the CDP “A List” for Climate Change and Water Security, plus an “A” rating in the CDP Supplier Engagement Assessment; Sustainalytics’ highest negligible-risk rating and recognition as an industry and regional ESG top-rated company for five years running; selection as a Constituent of the FTSE4Good Index Series; listing in the Hang Seng ESG 50 Index; and a Prime rating from ISS ESG Corporate Rating.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a premier global Contract Research, Development, and Manufacturing Organization (CRDMO). It provides comprehensive, end-to-end solutions that empower partners to discover, develop, and produce biologics—from initial concept to commercial launch—for patients globally.

Employing more than 12,000 skilled professionals across China, the United States, Ireland, Germany, Singapore, and Qatar, WuXi Biologics applies its technological expertise to deliver efficient and economical biologics discovery, development, and manufacturing services. As of December 31, 2025, the company was facilitating 945 integrated client projects, with 74 in Phase III clinical trials and 25 in commercial manufacturing.

WuXi Biologics considers Environmental, Social, and Governance (ESG) duties a fundamental part of its culture and corporate strategy, aspiring to be the ESG leader in the biologics CRDMO industry. Its facilities employ advanced biomanufacturing technologies and clean energy. An ESG committee chaired by the CEO guides the overarching ESG strategy and execution, strengthening the company’s dedication to sustainable practices.

For more information about WuXi Biologics, please visit:

SOURCE WuXi Biologics